Summit Therapeutics(MX:SMMT)
MX$290.000.00 (0.00%)
MX:SMMT
Summit Therapeutics stock drug pipeline
MX$290.00
At close:0.00 (0.00%)
Summit Therapeutics (SMMT) Drug Pipeline
1 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 β Safety and dosage c. Phase 2 β Effectiveness and side effects d. Phase 3 β Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 β Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Summit Therapeutics PLC (MX:SMMT) have in its pipeline
Summit Therapeutics MX:SMMT is currently developing the following drugs: Pembrolizumab, Enfortumab Vedotin, Ivonescimab Dose 1, Ivonescimab Dose 2, Ivonescimab Rp3d, Carboplatin, Ak138d1, Ivonescimab, Cetuximab, Daraxonrasib, Ivonescimab, Elironrasib, Zoldonrasib, Carboplatin/Cisplatin + Pemetrexed, Drug: Ivonescimab Injection, Drug: Bevacizumab Injection, Ivonescimab Injection, Pembrolizumab Injection, Oxaliplatin, Irinotecan, Capecitabine, Leucovorin, 5-Fluorouracil, Ak112, Ak117, Vancomycin, Ridinilazole. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

